©2020 Ivantis, Inc. Ivantis
and Hydrus are registered
trademarks of Ivantis, Inc.
All rights reserved.
IM-0008 Rev D
IN THE RACE AGAINST GLAUCOMA,
DURABILITY WINS
Glaucoma demands outcomes that endure. Results from the largest MIGS pivotal
trial to date have shown that the Hydrus® Microstent delivers the greatest improvement
compared to cataract surgery alone for IOP reduction and medication elimination at
24 months.
1-4,*
And now, at 4 years the Hydrus Microstent is the only MIGS device with results from
a pivotal trial showing a statistically significant reduction in risk of invasive secondary
glaucoma surgeries.†
When durability matters, choose the MIGS option that endures—Hydrus Microstent.
Delivering a new confidence.
